REPORT ID 3002

United States Opioid Antagonist Drug Market Report 2019

Publish Date
2019
Pages
102
Format
Electronic (PDF)

In this report, the United States Opioid Antagonist Drug market is valued at USD   XX million in 2019 and is expected to reach USD  XX million by the end of 2025, growing at a CAGR of  XX% between 2019 and 2025.

Geographically, this report splits the United States market into seven regions:
    The West
    Southwest
    The Middle Atlantic
    New England
    The South
    The Midwest
with sales (volume), revenue (value), market share and growth rate of Opioid Antagonist Drug in these regions, from   2019 to 2025 (forecast).

United States Opioid Antagonist Drug market competition by top manufacturers/players, with Opioid Antagonist Drug sales volume, price, revenue (Million USD) and market share for each manufacturer/player; the top players including
    Pfizer
    Conatus Pharmaceuticals
    Novartis
    Intercept Pharmaceuticals
    Allergan
    Immuron
    Takeda
    Gilead Sciences
    Genfit

On the basis of product, this report displays the production, revenue, price, market share and growth rate of each type, primarily split into
    Tablet
    Injection
On the basis on the end users/applications, this report focuses on the status and outlook for major applications/end users, sales volume, market share and growth rate for each application, including
    Hospital
    Medical Center

If you have any special requirements, please let us know and we will offer you the report as you want.

 
			   
Table of Contents

United States Opioid Antagonist Drug Market  Report 2019
1 Opioid Antagonist Drug Overview
    1.1 Product Overview and Scope of Opioid Antagonist Drug
    1.2 Classification of Opioid Antagonist Drug by Product Category
        1.2.1 United States Opioid Antagonist Drug Market Size (Sales Volume) Comparison by Type ( 2014-2024)
        1.2.2 United States Opioid Antagonist Drug Market Size (Sales Volume) Market Share by Type (Product Category)  in 2018
        1.2.3 Tablet
        1.2.4 Injection
    1.3 United States Opioid Antagonist Drug Market by Application/End Users
        1.3.1 United States Opioid Antagonist Drug Market Size (Consumption) and Market Share Comparison by Application ( 2014-2024)
        1.3.2 Hospital
        1.3.3 Medical Center
    1.4 United States Opioid Antagonist Drug Market by Region
        1.4.1 United States Opioid Antagonist Drug Market Size (Value) Comparison by Region ( 2014-2024)
        1.4.2 The West Opioid Antagonist Drug Status and Prospect ( 2014-2024)
        1.4.3 Southwest Opioid Antagonist Drug Status and Prospect ( 2014-2024)
        1.4.4 The Middle Atlantic Opioid Antagonist Drug Status and Prospect ( 2014-2024)
        1.4.5 New England Opioid Antagonist Drug Status and Prospect ( 2014-2024)
        1.4.6 The South Opioid Antagonist Drug Status and Prospect ( 2014-2024)
        1.4.7 The Midwest Opioid Antagonist Drug Status and Prospect ( 2014-2024)
    1.5 United States Market Size (Value and Volume) of Opioid Antagonist Drug ( 2014-2024)
        1.5.1 United States Opioid Antagonist Drug Sales and Growth Rate ( 2014-2024)
        1.5.2 United States Opioid Antagonist Drug Revenue and Growth Rate ( 2014-2024)

2 United States Opioid Antagonist Drug Market Competition by Players/Suppliers
    2.1 United States Opioid Antagonist Drug Sales and Market Share of Key Players/Suppliers ( 2014-2019)
    2.2 United States Opioid Antagonist Drug Revenue and Share by Players/Suppliers ( 2014-2019)
    2.3 United States Opioid Antagonist Drug Average Price by Players/Suppliers ( 2014-2019)
    2.4 United States Opioid Antagonist Drug Market Competitive Situation and Trends
        2.4.1 United States Opioid Antagonist Drug Market Concentration Rate
        2.4.2 United States Opioid Antagonist Drug Market Share of Top 3 and Top 5 Players/Suppliers
        2.4.3 Mergers & Acquisitions, Expansion in United States Market
    2.5 United States Players/Suppliers Opioid Antagonist Drug Manufacturing Base Distribution, Sales Area, Product Type

3 United States Opioid Antagonist Drug Sales (Volume) and Revenue (Value) by Region ( 2014-2019)
    3.1 United States Opioid Antagonist Drug Sales and Market Share by Region ( 2014-2019)
    3.2 United States Opioid Antagonist Drug Revenue and Market Share by Region ( 2014-2019)
    3.3 United States Opioid Antagonist Drug Price by Region ( 2014-2019)

4 United States Opioid Antagonist Drug Sales (Volume) and Revenue (Value) by Type (Product Category) ( 2014-2019)
    4.1 United States Opioid Antagonist Drug Sales and Market Share by Type (Product Category) ( 2014-2019)
    4.2 United States Opioid Antagonist Drug Revenue and Market Share by Type ( 2014-2019)
    4.3 United States Opioid Antagonist Drug Price by Type ( 2014-2019)
    4.4 United States Opioid Antagonist Drug Sales Growth Rate by Type ( 2014-2019)

5 United States Opioid Antagonist Drug Sales (Volume) by Application ( 2014-2019)
    5.1 United States Opioid Antagonist Drug Sales and Market Share by Application ( 2014-2019)
    5.2 United States Opioid Antagonist Drug Sales Growth Rate by Application ( 2014-2019)
    5.3 Market Drivers and Opportunities

6  United States Opioid Antagonist Drug Players/Suppliers Profiles and Sales Data
    6.1 Pfizer
        6.1.1 Company Basic Information, Manufacturing Base and Competitors
        6.1.2 Opioid Antagonist Drug Product Category, Application and Specification
            6.1.2.1 Product A
            6.1.2.2 Product B
        6.1.3 Pfizer Opioid Antagonist Drug Sales, Revenue, Price and Gross Margin ( 2014-2019)
        6.1.4 Main Business/Business Overview
    6.2 Conatus Pharmaceuticals
        6.2.2 Opioid Antagonist Drug Product Category, Application and Specification
            6.2.2.1 Product A
            6.2.2.2 Product B
        6.2.3 Conatus Pharmaceuticals Opioid Antagonist Drug Sales, Revenue, Price and Gross Margin ( 2014-2019)
        6.2.4 Main Business/Business Overview
    6.3 Novartis
        6.3.2 Opioid Antagonist Drug Product Category, Application and Specification
            6.3.2.1 Product A
            6.3.2.2 Product B
        6.3.3 Novartis Opioid Antagonist Drug Sales, Revenue, Price and Gross Margin ( 2014-2019)
        6.3.4 Main Business/Business Overview
    6.4 Intercept Pharmaceuticals
        6.4.2 Opioid Antagonist Drug Product Category, Application and Specification
            6.4.2.1 Product A
            6.4.2.2 Product B
        6.4.3 Intercept Pharmaceuticals Opioid Antagonist Drug Sales, Revenue, Price and Gross Margin ( 2014-2019)
        6.4.4 Main Business/Business Overview
    6.5 Allergan
        6.5.2 Opioid Antagonist Drug Product Category, Application and Specification
            6.5.2.1 Product A
            6.5.2.2 Product B
        6.5.3 Allergan Opioid Antagonist Drug Sales, Revenue, Price and Gross Margin ( 2014-2019)
        6.5.4 Main Business/Business Overview
    6.6 Immuron
        6.6.2 Opioid Antagonist Drug Product Category, Application and Specification
            6.6.2.1 Product A
            6.6.2.2 Product B
        6.6.3 Immuron Opioid Antagonist Drug Sales, Revenue, Price and Gross Margin ( 2014-2019)
        6.6.4 Main Business/Business Overview
    6.7 Takeda
        6.7.2 Opioid Antagonist Drug Product Category, Application and Specification
            6.7.2.1 Product A
            6.7.2.2 Product B
        6.7.3 Takeda Opioid Antagonist Drug Sales, Revenue, Price and Gross Margin ( 2014-2019)
        6.7.4 Main Business/Business Overview
    6.8 Gilead Sciences
        6.8.2 Opioid Antagonist Drug Product Category, Application and Specification
            6.8.2.1 Product A
            6.8.2.2 Product B
        6.8.3 Gilead Sciences Opioid Antagonist Drug Sales, Revenue, Price and Gross Margin ( 2014-2019)
        6.8.4 Main Business/Business Overview
    6.9 Genfit
        6.9.2 Opioid Antagonist Drug Product Category, Application and Specification
            6.9.2.1 Product A
            6.9.2.2 Product B
        6.9.3 Genfit Opioid Antagonist Drug Sales, Revenue, Price and Gross Margin ( 2014-2019)
        6.9.4 Main Business/Business Overview

7 Opioid Antagonist Drug Manufacturing Cost Analysis
    7.1 Opioid Antagonist Drug Key Raw Materials Analysis
        7.1.1 Key Raw Materials
        7.1.2 Price Trend of Key Raw Materials
        7.1.3 Key Suppliers of Raw Materials
        7.1.4 Market Concentration Rate of Raw Materials
    7.2 Proportion of Manufacturing Cost Structure
        7.2.1 Raw Materials
        7.2.2 Labor Cost
        7.2.3 Manufacturing Expenses
    7.3 Manufacturing Process Analysis of Opioid Antagonist Drug

8 Industrial Chain, Sourcing Strategy and Downstream Buyers
    8.1 Opioid Antagonist Drug Industrial Chain Analysis
    8.2 Upstream Raw Materials Sourcing
    8.3 Raw Materials Sources of Opioid Antagonist Drug Major Manufacturers  in 2018
    8.4 Downstream Buyers

9 Marketing Strategy Analysis, Distributors/Traders
    9.1 Marketing Channel
        9.1.1 Direct Marketing
        9.1.2 Indirect Marketing
        9.1.3 Marketing Channel Development Trend
    9.2 Market Positioning
        9.2.1 Pricing Strategy
        9.2.2 Brand Strategy
        9.2.3 Target Client
    9.3 Distributors/Traders List

10 Market Effect Factors Analysis
    10.1 Technology Progress/Risk
        10.1.1 Substitutes Threat
        10.1.2 Technology Progress in Related Industry
    10.2 Consumer Needs/Customer Preference Change
    10.3 Economic/Political Environmental Change

11 United States Opioid Antagonist Drug Market Size (Value and Volume) Forecast ( 2019-2025)
    11.1 United States Opioid Antagonist Drug Sales Volume, Revenue Forecast ( 2019-2025)
    11.2 United States Opioid Antagonist Drug Sales Volume Forecast by Type ( 2019-2025)
    11.3 United States Opioid Antagonist Drug Sales Volume Forecast by Application ( 2019-2025)
    11.4 United States Opioid Antagonist Drug Sales Volume Forecast by Region ( 2019-2025)

12 Research Findings and Conclusion

13 Appendix
    13.1 Methodology/Research Approach
        13.1.1 Research Programs/Design
        13.1.2 Market Size Estimation
        13.1.3 Market Breakdown and Data Triangulation
    13.2 Data Source
        13.2.1 Secondary Sources
        13.2.2 Primary Sources
    13.3 Disclaimer